Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Global Healthcare Company Licenses a Drug Delivery Technology Developed by UBC and the Centre for Drug Research and Development

In November 2010, the University of British Columbia (UBC) and the Centre for Drug Research and Development (CDRD), an NCE Centre of Excellence in Commercialization in Research, announced that Covidien, a leading global provider of healthcare products, had licensed an innovative drug-delivery platform technology invented by UBC researcher, Dr. Pieter Cullis.

“This technology would never have been developed without CDRD. The remarkable expertise and dedication of CDRD personnel took a project that was little more than a good idea to a fully developed product with demonstrable clinical potential,” noted Dr. Pieter Cullis, director, NanoMedicine Research Group, UBC.

“This technology can be applied to a wide variety of therapeutics, and allows drugs that cannot usually be loaded to be delivered via liposomal nanoparticle (LNP) technology. LNP delivery can enhance drug potency and reduce toxic side effects,” explained Dr. Cullis. “The current focus is on anti-cancer compounds, but the platform could be applied to many other therapeutic areas.”

“This licensing agreement further validates the successful collaboration model at CDRD, where we can provide drug development knowledge, technical infrastructure, commercialization expertise, and funding for researchers across Canada so they can carry out critical experiments to further advance their discoveries into new therapeutics,” said Karimah Es Sabar, senior vice president, Business and Strategic Affairs for CDRD.

 “CDRD is delighted to have enabled a commercialization pathway for this technology through a licensing agreement with Covidien,” added Ms. Es Sabar.

The This link will take you to another Web site Centre for Drug Research and Development (CDRD) is funded in part by the Centre of Excellence in Commercialization in Research (CECR) program, one of four national programs delivered by the NCE Secretariat. It provides drug development expertise and infrastructure to enable researchers from leading academic and health research institutions to advance promising discoveries. CDRD combines its drug development platform with a commercial arm, which licenses technologies from affiliated institutions and establishes working collaborations with other biotech and life-sciences companies.

Return to newsletter menu